Certara Stock News

The company celebrates the 12 scientists included in the Stanford/Elsevier top 2% cited researchers list The company celebrates the 12 scientists included in the Stanford/Elsevier top 2% cited researchers list

Certara, Inc. (CERT) Q3 2024 Earnings Conference Call Transcript

RADNOR, Pa., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today reported its financial results for the third quarter of fiscal year 2024.

RADNOR, Pa., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that Company management will participate in the Stephens Annual Investment Conference.

RADNOR, Pa., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced the appointment of John Reynders, PhD, to its Board of Directors, effective October 15, 2024.

RADNOR, Pa., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that it will release financial results for the third quarter of 2024 after the market close on Wednesday, November 6th, 2024. Company management will host a conference call to discuss financial results at 5:00PM ET.

Certara completes acquiring Chemaxon, a leading cheminformatics company that develops scientific informatics software used by the life sciences industry.

Certara shared the results from its collaboration with Ichnos Glenmark Innovation (IGI) on the first-in-human dose prediction and selection for ISB 2001.